Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma. Junhui Hu et al., Signal Transduct Target Ther, 2023. Precision ...
Saturation genome editing characterizes von Hippel–Lindau (VHL) coding variants and their associations with diseases. Function scores for 2,268 VHL single-nucleotide variants (SNVs) classify pathogenic alleles driving renal cell carcinoma and suggest new mechanisms by which variants impact function.
Pedro Barata interviews Yousef Zakharia about a phase 1/2 trial combining durvalumab and guadecitabine in metastatic kidney cancer. The study, conducted through the Big Ten Cancer Consortium, explores the potential synergy between hypomethylating agents and checkpoint inhibitors. Dr. Zakharia ...
Micro-AbstractPrognostic markers for treatment selection in metastatic renal cell carcinoma (mRCC) do not exist. This study evaluates c-Met ...
Oral metastatic lesions are very rare and are often diagnosed at a later stage, complicating treatment. Renal cell carcinoma (RCC) is the third ...
Researchers at the Francis Crick Institute have mapped all the possible outcomes of changes to a tumour-suppressing gene called VHL, the first step in a huge research endeavour to unpick the outcomes of tens of thousands of genetic variations in genes associated with cancer.
Vivek Subbiah, MD, discusses the rationale for combining sapanisertib with ziv-aflibercept in recurrent metastatic solid tumors, including kidney cancer.
Key opinion leaders analyze the latest advancements and research findings specific to Non-Clear Cell Renal Cell Carcinoma presented at the American Society of Clinical Oncology 2024 conference.
Key opinion leaders examine the application of tyrosine kinase inhibitors (TKIs) and evaluate first-line therapeutic approaches for renal cell carcinoma.
Background The role of cytoreductive nephrectomy (CN) in the treatment of metastatic renal cell carcinoma (mRCC) remains unclear in the immuno-oncology (IO) era. The results of two randomized trials, CARMENA and SURTIME, questioned the role and timing of CN. However, despite the latest ...
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.